Darmstadt, Germany, September 27, 2017 — Merck, a leading science and technology company, today announced an update on its participation in Horizon 2020, the EU Framework Program for Research and Innovation, to improve biopharmaceutical downstream processing.
The nextBioPharmDSP, a consortium of seven public and private organizations, is developing a more efficient, cost-effective and environmentally friendly downstream process to manufacture monoclonal antibodies and biosimilars. Efforts focused on advanced analytical tools for process monitoring have already led to more publications and two patent applications, and additional publications and patent applications are being prepared in other areas of the project. The consortium has received approval for its 18-month periodical report, and the project was highlighted as a success story by the European Commission Directorate-General for Research and Innovation.
“The biopharmaceutical industry is facing pressure to reduce manufacturing costs and deliver greater efficiencies, all while being environmentally responsible,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “It is important for companies like Merck and our customers to help address industry-wide challenges and accelerate the process of getting drugs to patients in need. Through the Horizon 2020 program, consortium members are already delivering important advances for downstream processing.”
Collaboration outcomes will include reduction in the size and number of downstream unit operations as well as elimination of the need for centrifugation. Alternative approaches for the capture step are expected to improve efficiency and reduce the need for expensive resin volume. Capture via precipitation is also being studied as a replacement for protein A chromatography.
A disposable continuous chromatography system is in development with novel analytical tools and sensors, which are also implemented in other parts of downstream process. Single-use disposable technology for all downstream processing operations will be evaluated and flow-through approaches for polishing steps implemented, to remove impurities in a continuous way. Selected approaches will be integrated in a connected continuous downstream single-use process.
“Next generation bioprocessing strategies will improve our industry’s ability to efficiently and cost-effectively supply high quality medicines,” said Uroš Urleb, Global Head Technical Development Biosimilars in the Biologics Technical Development and Manufacturing Unit at Novartis. “The consortium is delivering new approaches to the conventional manufacturing workflow and we expect the results of our efforts will help address variations in capacity needs, enable sustained drug supply and offer important environmental benefits.”
The nextBioPharmDSP is part of the Horizon 2020 initiative, the largest EU-based program of its kind to date with nearly €80 billion of funding available over seven years (2014 to 2020). The program seeks to ensure Europe produces world-class science by removing barriers to innovation and collaboration between public and private sectors. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.
The project is coordinated by Lek Pharmaceuticals, a Sandoz company in Slovenia. Consortium members include Sandoz GmbH (Austria), University of Natural Resources and Life Sciences, Vienna (Austria), Karlsruhe Institute of Technology (Germany), National Institute of Chemistry (Slovenia) and National Systems srl (Italy). Merck participates in the consortium through its French subsidiary, Millipore S.A.S. For more information, please visit the project website at http://nextbiopharmdsp.eu/.
Acknowledgement:This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 635557.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2018, Merck KGaA, Darmstadt, Germany generated sales of €14.8 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.